Tafasitamab, Lenalidomide, Rituximab, and Orelabrutinib for Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Key facts
- Who runs it
- Sun Yat-sen University
- Where
- China3 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Not yet recruiting
- Phase
- Phase 2
- People taking part
- 29 people, planned
- Starts
- 1 Dec 2026
- Expected to end
- 1 Dec 2029
- Type of study
- Interventional
- Treatments tested
- Tafasitamab
- Lenalidomide
- Rituximab
- Orelabrutinib
- Record updated
- 16 November 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (11)Hide the full registry criteria
Who can take part
- Willing to participate in the clinical study and signed informed consent
- Age ≥18 years, no gender restrictions
- Histologically confirmed relapsed or refractory diffuse large B-cell lymphoma; ineligible for or unable to access autologous stem cell transplantation (ASCT), chimeric antigen receptor T-cell (CAR-T) therapy
- Has at least one measurable or assessable lesion
- Eastern Cooperative Oncology Group performance status (ECOG PS) score ≤
- Adequate major organ function
Who cannot take part
- Disease progression following prior frontline treatment with a Bruton tyrosine kinase inhibitor (BTKi)
- Active human immunodeficiency virus (HIV) or hepatitis C virus (HCV) infection
- Inability to swallow capsules or significant gastrointestinal impairment that may affect drug absorption
- Other progressive malignancy requiring active treatment
- DLBCL with central nervous system involvement or Burkitt lymphoma
Eligibility questionnaire
From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Age
- Diffuse large B cell lymphoma
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This is a Phase II, Single-Arm, Open-Label, Prospective, Multicentre Study to Evaluate the Safety and Efficacy of Tafasitamab (TAFA) combined with Lenalidomide, Rituximab, and Orelabrutinib in Participants with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL).
The group in the trial
- Tafasitamab in combination with Lenalidomide, Rituximab and OrelabrutinibTreatment being tested
Participants will receive tafasitamab in combination with lenalidomide, rituximab and orelabrutinib for 4 cycles, and then receive tafasitamab and lenalidomide for additional 8 cycles. Each treatment cycle is 28 days.
Treatment: Tafasitamab, Lenalidomide, Rituximab, and Orelabrutinib
Next steps
For your doctor
Doctor ask sheet
A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.
PDF, US Letter, 1 to 2 pages. A4 size
For the study team
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Prospective, Multicenter, Phase II Clinical Study of Tafasitamab, Lenalidomide, Rituximab, and Orelabrutinib in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- Criteria questions
- Built from NCT07938619, who can take part
- Record updated
- 16 November 2026